Reporting Endometrial Cells in Women 40 Years and Older Assessing the Clinical Usefulness of Bethesda 2001
|
|
- Daniella Allison
- 5 years ago
- Views:
Transcription
1 Anatomic Pathology / THE EFFECT OF BETHESDA 2001 ON REPORTING OF ENDOMETRIAL CELLS Reporting Endometrial Cells in Women 40 Years and Older Assessing the Clinical Usefulness of Bethesda 2001 Aylin Simsir, MD, 1 William Carter, 2 Paul Elgert, CT(ASCP), 1 and Joan Cangiarella, MD 1 Key Words: Endometrial cells; Cervicovaginal smears; Bethesda System; Hormone replacement therapy; Tamoxifen Abstract We assessed the usefulness of revised Bethesda System reporting of exfoliated benign endometrial cells (EMs) in postmenopausal women. Cervicovaginal cytology specimens with benign EMs in postmenopausal women and out-of-phase EMs in premenopausal women 40 years and older were identified. Cases with histologic follow-up within 12 months were selected. There was tissue follow-up for 130 postmenopausal women: 10 (7.7%) had significant findings (endometrial adenocarcinoma, 6 [2 (33%) in asymptomatic women]; complex atypical endometrial hyperplasia [CAH], 3; leiomyosarcoma, 1); 20 were receiving hormone replacement therapy (HRT; n = 15) or tamoxifen (n = 5); 2 (10%) had significant pathology (endometrial adenocarcinoma, 1; CAH, 1). Eight not taking hormones (7.3%) had significant pathology (adenocarcinoma, 5; CAH, 2; leiomyosarcoma, 1). There were follow-up data for 96 premenopausal women; only 1 (who had vaginal bleeding) had significant pathology (CAH). The difference in incidence of preneoplastic and neoplastic conditions after a cytologic interpretation of benign EM between postmenopausal and premenopausal women was significant (P.025); There was no difference between postmenopausal women receiving or not receiving HRT (P >.05). Reporting benign EMs for premenopausal women 40 years and older has no clinical significance but does for postmenopausal women, regardless of HRT and symptoms. Benign-appearing endometrial cells commonly are seen in cervicovaginal cytologic (CV) specimens obtained from women of reproductive age in the proliferative phase (days 1-14) of the menstrual cycle. Historically, the presence of cytologically benign-appearing endometrial cells, outside the proliferative phase and in postmenopausal women, was reported to the clinician regardless of patient age. With the inception of the 1991 Bethesda System for the reporting of CV abnormalities, the reporting of benign endometrial cells was modified to state the presence of exfoliated endometrial cells only in postmenopausal women. 1 This revision was based on the findings of several studies that suggested that spontaneously exfoliated benign endometrial cells might indicate endometrial pathology in postmenopausal women, necessitating endometrial sampling. 2-7 Furthermore, it has been noted that while most women with endometrial adenocarcinoma are symptomatic, in a small portion of women, exfoliated benign endometrial cells in a CV specimen might be the only sign of underlying endometrial pathology; thus, their presence requires further investigation. 2,6,8 In 2001, the reporting of benign endometrial cells was further modified (TBS 2001) to include all women 40 years and older. 9 The rationale behind this change was that an individual woman s risk factors for endometrial adenocarcinoma, the clinical symptoms, hormonal intake history, menopausal status, and the date of the last menstrual period (LMP) often are unclear or unavailable to the cytopathology laboratory. Thus, the significance of exfoliated benign endometrial cells can be interpreted only by the clinician. A major concern with the reporting of cytologically benign-appearing endometrial cells in all women 40 years and older has been the potential for unnecessary clinical Am J Clin Pathol 2005;123:
2 Simsir et al / THE EFFECT OF BETHESDA 2001 ON REPORTING OF ENDOMETRIAL CELLS concern and intervention because more recent outcome studies have shown that this finding in premenopausal women has no clinical relevance and, in many cases, creates a management dilemma for clinicians. 8,10 In addition, many older studies showing the association of exfoliated benign endometrial cells with endometrial adenocarcinoma were based on data obtained before the widespread use of exogenous hormonal replacement therapy (HRT) and hormonal treatment with tamoxifen. Recently, HRT was shown to be associated with an increased prevalence of exfoliated benign endometrial cells on CV specimens and a lower incidence of endometrial pathology in comparison with specimens from women who did not use HRT. 11,12 The converse was true for patients taking tamoxifen. In this group, the presence of benign endometrial cells on CV smears was associated with an increased risk of the development of endometrial adenocarcinoma. 13 We studied the clinical significance of modifying the reporting of endometrial cells in TBS 2001 by comparing the outcome in postmenopausal women with premenopausal women 40 years and older. We also evaluated the clinical significance of exfoliated benign endometrial cells in CV specimens in women receiving hormonal therapy. Materials and Methods The computerized databases of New York University Medical Center and Bellevue Hospital, New York, NY, were searched for cases from January 1998 to June 2002 with CV specimen (liquid-based cytology and conventional Papanicolaou smear) interpretations of endometrial cells in postmenopausal women and endometrial cells out of phase or endometrial cells, not otherwise specified in premenopausal women 40 years and older. The term endometrial cells, not otherwise specified was used for women with an unknown LMP date. Samples from postmenopausal women with unknown hormonal intake status and from women with atypical or malignant endometrial cells in CV specimens and menstrual smears with known LMPs were excluded from the study. Only samples from women with known follow-up histologic examination (endometrial curettage, endometrial biopsy, polypectomy, myomectomy, or hysterectomy) within 12 months of the CV specimen were included. Hormonal intake history and symptoms (eg, vaginal bleeding, pelvic mass) were obtained from CV specimen and surgical pathology requisition forms. Two groups were created: group 1, samples from postmenopausal women with endometrial cells on CV specimens; group 2, samples from premenopausal women 40 years and older with endometrial cells out of phase or endometrial cells, not otherwise specified on CV specimens. The outcomes in groups 1 and 2 were compared. In addition, group 1 was divided into women receiving (group 1A) and women not receiving (group 1B) HRT or tamoxifen. The 2 subgroups in group 1 were compared. Statistical analysis was performed using the χ 2 test. Results Clinical Data We identified 576 cases in group 1. Follow-up histologic data were available for 130 women (22.6%). We identified 624 cases in group 2. Follow-up histologic data were available for 96 (15.4%). In group 1, 25 women had vaginal bleeding (4.3%); 1 woman was receiving HRT. In group 2, 12 women had vaginal bleeding (1.9%). Cytohistologic Data Group 1 Results are summarized in Table 1. Of 130 women, 25 (19.2%) had no pathologic findings, 95 (73.1%) had benign findings, and 10 (7.7%) had significant pathologic findings. The benign findings included 64 endometrial polyps and 31 leiomyomas. The significant findings included 6 cases of endometrial adenocarcinoma, 3 of complex atypical endometrial hyperplasia, and 1 of leiomyosarcoma. Of the 6 endometrial adenocarcinomas, 2 (33%) occurred in asymptomatic women. Of 130 cases with follow-up data, 110 were included in group 1A and 20 in group 1B. Group 1A Results are summarized in Table 2. Of 110 patients, 14 (12.7%) had no pathologic findings and 88 (80.0%) had benign findings, including 58 endometrial polyps and 30 leiomyomas. Eight cases (7.3%) had significant pathology, including 5 cases of endometrial adenocarcinoma, 2 of complex atypical endometrial hyperplasia, and 1 of leiomyosarcoma. Table 1 Histologic Follow-up in Women With Benign Endometrial Cells on Cervicovaginal Smears: Comparison of Postmenopausal Women With Premenopausal Women 40 Years and Older * Group 1 (n = 130) Group 2 (n = 96) No pathologic findings 25 (19.2) 48 (50) Benign pathologic findings 95 (73.1) 47 (49) Preneoplastic and neoplastic 10 (7.7) 1 (1) conditions * Group 1, postmenopausal women; group 2, premenopausal women 40 years and older. Data are given as number (percentage). P Am J Clin Pathol 2005;123: Downloaded 572 from
3 Anatomic Pathology / ORIGINAL ARTICLE Group 1B Results are summarized in Table 2. Eleven (55%) had no pathologic findings, and 7 (35%) had benign findings, including 6 endometrial polyps and 1 leiomyoma. Two (10%) had significant pathology, including 1 endometrial adenocarcinoma and 1 complex atypical endometrial hyperplasia. Both of these cases occurred in women receiving HRT. No preneoplastic or neoplastic lesions were detected in women taking tamoxifen. Group 2 Results are summarized in Table 1. Of 96 cases, 48 (50%) had no pathologic findings, 47 (49%) had benign findings, and 1 (1%) had significant pathology. The benign findings included 27 endometrial polyps, 18 leiomyomas, 1 chronic endometritis, and 1 simple endometrial hyperplasia without atypia. The significant case showed complex atypical endometrial hyperplasia. This patient had vaginal bleeding. Summary of Findings The incidence of preneoplastic and neoplastic conditions after a cytologic interpretation of benign endometrial cells was higher in postmenopausal women than in premenopausal women 40 years and older (P.025). Only 1 woman had complex atypical endometrial hyperplasia in group 2, and she was symptomatic with vaginal bleeding. A diagnostic procedure was done regardless of the CV specimen findings. There was no difference in the incidence of preneoplastic and neoplastic conditions in postmenopausal women receiving or not receiving hormonal therapy (P >.05). Discussion The 1991 Bethesda System recommended reporting of exfoliated benign endometrial cells in postmenopausal women only. 1 The 2001 Bethesda System was revised to include reporting exfoliated benign endometrial cells in all women 40 years and older regardless of the date of the LMP. 9 Table 2 Histologic Follow-up in Postmenopausal Women With Benign Endometrial Cells on Cervicovaginal Smears: Comparison of Women Taking Hormones With Women Not Taking Hormones * Group 1A (n = 110) Group 1B (n = 20) No pathologic findings 14 (12.7) 11 (55) Benign pathologic findings 88 (80.0) 7 (35) Preneoplastic and neoplastic 8 (7.3) 2 (10) conditions * Group 1A, postmenopausal women not receiving hormone replacement therapy or tamoxifen; group 1B, postmenopausal women taking hormone replacement therapy or tamoxifen. Data are given as number (percentage). P >.05. This change was deemed necessary because menstrual status, exogenous hormone therapy, and other clinical risk factors associated with endometrial adenocarcinoma often are unknown to the laboratory. However, the proper clinical management of exfoliated benign endometrial cells noted in CV specimens is controversial. This is due mostly to the markedly variable reported incidences (0.8%-12%) of atypical endometrial hyperplasia and endometrial adenocarcinoma detected in postmenopausal women after a cytologic finding of exfoliated endometrial cells in CV specimens This issue becomes even more complicated for postmenopausal women who are asymptomatic or receiving HRT and for women who have not yet entered menopause ,17 Thus, the clinical usefulness of reporting exfoliated endometrial cells as outlined in the TBS 2001 is being debated. Our study indicated that the reporting of benign endometrial cells on CV smears in premenopausal women 40 years and older has no clinical relevance. Only 1 premenopausal woman (1%) in our study had significant endometrial pathology. This woman had vaginal bleeding, and, thus, further workup was initiated regardless of the CV smear finding. This contrasts with postmenopausal women in whom significant endometrial pathology was noted in 7.7%. Furthermore, 33% of the postmenopausal women with endometrial adenocarcinoma (2/6) were asymptomatic. Our results for postmenopausal women are in agreement with previously reported data. 2,3,5,6,16-20 More recently, a review of the abstracts presented at the 2004 American Society of Cytopathology meeting revealed 5 studies that evaluated the clinical significance of reporting endometrial cells in women 40 years and older All investigators unanimously reported the incidence of clinically significant endometrial lesions (hyperplasia and adenocarcinoma) in premenopausal women to be very low, ranging from 0% to 1.4%. In addition, all adenocarcinomas detected were associated with symptoms, and in each case, symptoms preceded the cytologic findings in defining the clinical management. 23,24 TBS 2001 led to an increase in the number of women who underwent endometrial sampling as a result of decreasing the age cutoff for reporting of endometrial cells to 40 years. 21,22 The increase in the number of endometrial sampling procedures occurred despite an educational note on the cytology report about the uncertain clinical implications of this finding in premenopausal women. 22 The management of asymptomatic women with exfoliated benign endometrial cells in their CV specimens is not well defined. Most women with endometrial hyperplasia and adenocarcinoma have vaginal bleeding, but a minority are asymptomatic. 2,5,8 In our study, in contrast with premenopausal women 40 years and older, one third of postmenopausal women with endometrial adenocarcinoma were asymptomatic. Am J Clin Pathol 2005;123:
4 Simsir et al / THE EFFECT OF BETHESDA 2001 ON REPORTING OF ENDOMETRIAL CELLS The incidence of endometrial adenocarcinoma in asymptomatic women who have normal endometrial cells in their CV specimens ranges from 1% to 4.3%. 2,6 Some recommend endometrial evaluation for all asymptomatic postmenopausal women with normal endometrial cells in their CV specimens. 2,5,17 Others advocate no additional follow-up for asymptomatic women based on negative long-term follow-up. 8 In a study of 44 asymptomatic women who had exfoliated endometrial cells in their CV smears with a 3-year follow-up, Gomez- Fernandez et al 8 had no cases with endometrial hyperplasia or adenocarcinoma. The authors emphasized that the reporting of normal endometrial cells in CV specimens creates unnecessary patient anxiety and leads to unjustifiable diagnostic procedures. Ashfaq et al 14 found significant pathology in 12% of postmenopausal women with normal endometrial cells in CV specimens, but all women had abnormal vaginal bleeding. Our study indicates that postmenopausal women who are asymptomatic and have exfoliated endometrial cells in CV specimens require further evaluation, whereas this finding may be ignored in asymptomatic premenopausal women. Another controversial area is the significance of benign endometrial cells in CV specimens of postmenopausal women receiving HRT. 5,11,12,14,17,26,27 We found no difference in the incidence of endometrial preneoplasia and neoplasia in postmenopausal women receiving HRT and those not receiving HRT. Our results are similar to those reported by Yancey et al. 5 Others have reported a lower incidence of endometrial pathology in postmenopausal women receiving HRT. 11,14,17 Ashfaq et al 14 noted significant endometrial pathology (hyperplasia with atypia and adenocarcinoma) in 2% of postmenopausal women receiving HRT vs 9% of postmenopausal women not receiving HRT. Mount et al 11 reported that despite the increased prevalence of benign endometrial cells in CV smears of postmenopausal women receiving HRT, the incidence of endometrial pathology was very low. It is noteworthy to clarify that these authors defined endometrial pathology to include endometrial polyps, simple and complex endometrial hyperplasia with and without atypia, and endometrial adenocarcinoma. In fact, there was no significant difference in the prevalence of endometrial adenocarcinoma between postmenopausal women with benign endometrial cells in CV smears who received HRT and those who did not (1.5% vs 3.7%; P =.175). Brogi et al 17 did not identify any cases of atypical or complex endometrial hyperplasia or adenocarcinoma in 22 postmenopausal women who had endometrial cells in their CV specimens while receiving HRT. A caveat of our study and of the study by Brogi et al 17 is the low number of postmenopausal women receiving HRT for whom tissue follow-up was available. However, based on the data presented herein, it is our opinion that postmenopausal women receiving HRT who shed benign endometrial cells should undergo endometrial sampling. The literature on follow-up of women who are taking tamoxifen and have exfoliated benign endometrial cells in their CV specimens is scant. 13 Tamoxifen is a nonsteroidal antiestrogen used in the treatment of breast cancer. The presence of endometrial cells in the CV specimens of women taking tamoxifen is associated with a higher risk of development of endometrial adenocarcinoma. 13 Abadi et al 13 showed that the diagnosis of endometrial adenocarcinoma was preceded by exfoliated endometrial cells in CV specimens in 28% of women with breast cancer treated with tamoxifen in comparison with 7% of women with breast cancer and tamoxifen therapy who did not develop endometrial carcinoma. We did not find any cases of endometrial hyperplasia or adenocarcinoma in women who were taking tamoxifen in our study. However, the number of women taking tamoxifen was limited. Our findings indicate that the reporting of benign endometrial cells in CV cytology specimens of premenopausal women 40 years and older has no clinical significance. This is in contrast with findings for postmenopausal women. Postmenopausal women who shed cytologically normal-appearing endometrial cells have a significant risk of preneoplastic and neoplastic endometrial disease regardless of their hormonal intake status and lack of symptoms. Therefore, although premenopausal women can be safely followed up conservatively in the absence of symptoms, all postmenopausal women with spontaneously exfoliated endometrial cells in their CV specimens should undergo endometrial sampling regardless of HRT status and symptoms. From the 1 Department of Pathology, Division of Cytopathology, New York University School of Medicine, New York, NY; and the 2 University of Alabama School of Medicine, Birmingham. Address reprint requests to Dr Cangiarella: NYU Medical Center, 530 First Ave, Skirball (West Tower), Suite 10U, New York, NY References 1. Kurman RJ, Solomon D. The Bethesda System for Reporting Cervical and Vaginal Cytologic Diagnosis. New York, NY: Springer-Verlag; 1994: Cherkis RC, Patten SF Jr, Andrews TJ, et al. Significance of normal endometrial cells detected by cervical cytology. Obstet Gynecol. 1988;71: Gondos B, King EB. Significance of endometrial cells in cervicovaginal smears. Ann Clin Lab Sci. 1977;21: McGowan L. The current efficacy of the cervical-vaginal cytosmear to detect endometrial cancer. Acta Cytol. 1964;8: Yancey M, Magelssen D, Demaurez A, et al. Classification of endometrial cells on cervical cytology. Obstet Gynecol. 1990;76: Zucker PK, Kasdon EJ, Feldstein ML. The validity of Pap smear parameters as predictors of endometrial pathology in menopausal women. Cancer. 1985;56: Am J Clin Pathol 2005;123: Downloaded 574 from
5 Anatomic Pathology / ORIGINAL ARTICLE 7. Ng AB, Reagan JW, Hawliczek S, et al. Significance of endometrial cells in the detection of endometrial carcinoma and its precursors. Acta Cytol. 1974;18: Gomez-Fernandez CR, Ganjei-Azar P, Capote-Dishaw J, et al. Reporting normal endometrial cells in Pap smears: an outcome appraisal. Gynecol Oncol. 1999;74: Solomon D, Davey D, Kurman R, et al, and Forum Group Members, Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287: Karim BO, Burroughs FH, Rosenthal DL, et al. Endometrialtype cells in cervico-vaginal smears: clinical significance and cytopathologic correlates. Diagn Cytopathol. 2002;26: Mount SL, Wegner EK, Eltabbakh GH, et al. Significant increase of benign endometrial cells on Papanicolaou smears in women using hormone replacement therapy. Obstet Gynecol. 2002;100: Sarode VR, Rader AE, Rose PG, et al. Significance of cytologically normal endometrial cells in cervical smears from postmenopausal women. Acta Cytol. 2001;45: Abadi MA, Barakat RR, Saigo PE. Effects of tamoxifen on cervicovaginal smears from patients with breast cancer. Acta Cytol. 2000;44: Ashfaq R, Sharma S, Dulley T, et al. Clinical relevance of benign endometrial cells in postmenopausal women. Diagn Cytopathol. 2001;25: Chang A, Sandweiss L, Bose S. Cytologically benign endometrial cells in the Papanicolaou smears of postmenopausal women. Gynecol Oncol. 2001;80: Wu HH, Schuetz MJ III, Cramer H. Significance of benign endometrial cells in Pap smears from postmenopausal women. J Reprod Med. 2001;46: Brogi E, Tambouret R, Bell DA. Classification of benign endometrial glandular cells in cervical smears from postmenopausal women. Cancer. 2002;96: DuBeshter B, Warshol DP, Angel C, et al. Endometrial carcinoma: the relevance of cervical cytology. Obstet Gynecol. 1991;77: Kerpsack JT, Finan MA, Kline RC. Correlation between endometrial cells on Papanicolaou smear and endometrial carcinoma. South Med J. 1998;91: Reagan JW. Cytologic aspects of endometrial neoplasia [proceedings]. Acta Cytol. 1980;24: Bean S, Connolly K, Roberson J, et al. Incidence and clinical significance of normal endometrial cells in patients 40 years and older [abstract]. Acta Cytol. 2004;48: Papillo JL, Harmon ML, Mount SL, et al. Reporting of endometrial cells in women results in increased endometrial biopsies with low yield [abstract]. Acta Cytol. 2004;48: Long KD, Biscotti C. An analysis of the Bethesda System 2001 guideline for reporting benign endometrial cells [abstract]. Acta Cytol. 2004;48: Saad RS, Mahdavy M, Takei H, et al. Endometrial cells in cervical specimens of women > 40 years of age [abstract]. Acta Cytol. 2004;48: Ely KA, Bregman S, Arnott CK. Clinical significance of reporting endometrial cells in patients over the age of 40 and its influence on the decision to biopsy [abstract]. Acta Cytol. 2004;48: Eddy G, Wojtowycz MA, Piraino PS, et al. Papanicolaou smears by the Bethesda System in endometrial malignancy: utility and prognostic importance. Obstet Gynecol. 1997;90: Montz FJM. Significance of normal endometrial cells in cervical cytology from asymptomatic postmenopausal women receiving hormone replacement therapy. Gynecol Oncol. 2001;81: Am J Clin Pathol 2005;123:
Classification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women
60 CANCER CYTOPATHOLOGY Classification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women Edi Brogi, M.D., Ph.D. Rosemary Tambouret, M.D. Debra A. Bell, M.D. Department
More informationEndometrial Cells in Pap smears- Role in prediction of Endometrial Pathology- A three year study
International Journal of Scientific and Research Publications, Volume 5, Issue 9, September 2015 1 Endometrial Cells in Pap smears- Role in prediction of Endometrial Pathology- A three year study Dr. Manjari
More informationThe Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
More informationSummary CHAPTER 1. Introduction
Summary This thesis aims to evaluate the diagnostic work-up in postmenopausal women presenting with abnormal vaginal bleeding. The Society of Dutch Obstetrics and Gynaecology composed a guideline, which
More informationIndex. Cytoplasm, nonepithelial malignant tumor features 70
Accurette device 23 Adenosarcoma, differential diagnosis 80, 81 Arias-Stella reaction 65 Atypical endocervical cells 8 Atypical endometrial cells 8 Atypical glandular cells (AGC) 8, 9 Atypical glandular
More informationThe diagnostic category of atypical squamous cells of undetermined
100 CANCER CYTOPATHOLOGY Significance of a Diagnosis of Atypical Squamous Cells of Undetermined Significance for Papanicolaou Smears in Perimenopausal and Postmenopausal Women Jeffrey T. Keating, M.D.
More informationSignificance of Endometrial Cells in Cervicovaginal Smears
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 7,No. 6 Copyright 1977, Institute for Clinical Science Cervicovaginal Smears BERNARD GONDOS, M.D. and EILEEN B. KING, M.D. Department of Pathology, University
More informationChapter 10: Pap Test Results
Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the
More informationRESEARCH ARTICLE. Pap Smears in Endometrial Adenocarcinoma: Does It Have a Role?
DOI:10.22034/APJCP.2017.18.4.1145 Pap smears in Endometrial Adenocarcinoma RESEARCH ARTICLE Pap Smears in Endometrial Adenocarcinoma: Does It Have a Role? Asma Nadaf*, Hephzibah Rani, Parinitha SS, Ravikala
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationAGC Subclasses and Risk of Invasive Cancers
AGC Subclasses and Risk of Invasive Cancers Xuezhi (Daniel) Jiang, MD, PhD Associate Professor of Obstetrics & Gynecology The Reading Hospital of Tower Health Thomas Jefferson University Reading, PA Disclosures
More informationLong-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance
Anatomic Pathology / LONG-TERM OUTCOME WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Long-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance Stephen
More informationbleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the
Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis
More informationThe prevalence and spectrum of atypical glandular cells in Dubai hospital: A local experience
DOI: 10.15415/jmrh.2016.31006 The prevalence and spectrum of atypical glandular cells in Dubai hospital: A local experience RAVIRANI SAMUEL 1, MANAL M.M. ABDULRAZZAQ 1, BADR ABDULLGAFFAR 2, HASSAN Y. HOTAIT
More informationPreface to the Second Edition
Preface to the Second Edition This second edition of Diagnosis of Endometrial Biopsies and Curettings: A Practical Approach follows a number of favorable comments we received about the first edition. As
More information2016 myresearch Science Internship Program: Laboratory Medicine. Civic Education Office of Government and Community Relations
2016 myresearch Science Internship Program: Laboratory Medicine Civic Education Office of Government and Community Relations Aliya Ansari Science Internship Program: Laboratory Medicine Cytologic Differentiation
More informationInternational Journal of Biological & Medical Research
Int J Biol Med Res. ; 2(3): 757-761 Int J Biol Med Res www.biomedscidirect.com Volume 2, Issue 3, July BioMedSciDirect Publications Contents lists available at BioMedSciDirect Publications International
More informationANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION
Electronic Journal of Pharmacology and Therapy Vol 4, 15-20 (2011) ISSN: 0973-9890 (Available online at wwwtcrjournalscom) Clinical Article ndexed in: ProQuest database Abstract, USA (ProQuest Science
More informationGlandular lesions in cervical cytology. Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia
Glandular lesions in cervical cytology Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia 2nd PANNONIA CONGRESS OF PATHOLOGY, SIÓFOK, HUNGARY, 17-19 MAY
More informationEndometrial cancer in women 45 years of age or younger: A clinicopathological analysis
American Journal of Obstetrics and Gynecology (2005) 193, 1640 4 www.ajog.org Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis Gilbert P. Pellerin, MD, Michael A.
More informationAn Abnormal Cervicovaginal Cytology Smear in Uterine Carcinosarcoma Is an Adverse Prognostic Sign Analysis of 25 Cases
Anatomic Pathology / CYTOLOGY OF CARCINOSARCOMA OF UTERUS An Abnormal Cervicovaginal Cytology Smear in Uterine Carcinosarcoma Is an Adverse Prognostic Sign Analysis of 25 Cases Matthew J. Snyder, MD, 1
More informationEvaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear
The Korean Journal of Pathology 2010; 44: 528-35 DOI: 10.4132/KoreanJPathol.2010.44.5.528 Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationArticle begins on next page
Association of cervical microglandular hyperplasia with exogenous progestin exposure Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters.
More informationCervical Cancer Prevention in the 21 st Century Changing Paradigms
Cervical Cancer Prevention in the 21 st Century Changing Paradigms Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M.
More informationThe ABCs of TBS. A Novice's Guide to the Bethesda System
CE U P D A T E W O M E N ' S HEALTH III Julia Woodruff Wildes, MD The ABCs of TBS A Novice's Guide to the Bethesda System This is the third and final article in a three-part series on women's health. The
More informationIn 1988, The Bethesda System (TBS) introduced the phrase atypical
CANCER CYTOPATHOLOGY 93 Should the Cytologic Diagnosis of Atypical Squamous Cells of Undetermined Significance Be Qualified? An Assessment Including Comparison between Conventional and Liquid-Based Technologies
More informationAtypical And Suspicious Categories In Fine Needle Aspiration Cytology Of The Breast
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-853, p-issn: 2279-861.Volume 15, Issue 1 Ver. III (October. 216), PP 57-61 www.iosrjournals.org Atypical And Suspicious Categories in
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationMolly A. Brewer DVM, MD, MS Chair and Professor Department of Obstetrics and Gynecology University of Connecticut School of Medicine
Molly A. Brewer DVM, MD, MS Chair and Professor Department of Obstetrics and Gynecology University of Connecticut School of Medicine Review causes of abnormal uterine bleeding: Adolescent Reproductive
More informationAn audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia
DOI:10.1111/j.1365-2303.2009.00695.x An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia S. A. Thiryayi, J. Marshall and D. N. Rana Manchester
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationManagement of Endometrial Hyperplasia
Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New
More informationThe Bethesda System: Updates for th Cytopathology Congress Bursa, Turkey October 14, 2015
HARVARD MEDICAL SCHOOL The Bethesda System: Updates for 2015 6th Cytopathology Congress Bursa, Turkey October 14, 2015 David C. Wilbur, M.D. Dept. of Pathology Massachusetts General Hospital DISCLOSURES
More informationIncidence and Evaluation of an AGUS Papanicolaou Smear in Primary Care
Incidence and Evaluation of an AGUS Papanicolaou Smear in Primary Care Anthony Valdini, MD, MS, Carla Vaccaro, MD, Geoffrey Pechinsky, MD, and Veronica Abernathy, MPH Background: The category atypical
More informationCervical cytology screening has led to a reduction in cancer mortality
CANCER CYTOPATHOLOGY 105 ThinPrep Pap Test Performance and Biopsy Follow-Up in a University Hospital A. Betts Carpenter, M.D., Ph.D. Diane D. Davey, M.D. Department of Pathology and Laboratory Medicine,
More informationGynecologic Decision Making Based on Sonographic Findings
Gynecologic Decision Making Based on Sonographic Findings Mindy Goldman, MD Department of Obstetrics & Gynecology & Vickie A. Feldstein, MD Department of Radiology University of California, San Francisco
More informationHKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists
HKCOG Guidelines Guidelines on the Management of An Abnormal Cervical Smear Number 3 revised November 2002 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College of
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationA clinical review of borderline glandular cells on cervical cytology
British Journal of Obstetrics and Gynaecology May 2000, Vol07, pp. 605-609 A clinical review of borderline glandular cells on cervical cytology D. Kusnah A. Mohammed Research Senior House Oflcer, Ofer
More informationCervicovaginal Flora Comparison of Conventional Pap Smears and a Liquid-Based Thin-Layer Preparation
Anatomic Pathology / CERVICOVAGINAL FLORA Cervicovaginal Flora Comparison of Conventional Pap Smears and a Liquid-Based Thin-Layer Preparation Hidehiro Takei, MD, 1,2 Bernardo Ruiz, MD, PhD, 2 and John
More informationGYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital
GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital and Bioreference Labs (Houston) Department of Pathology
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationAtypical Epithelial Cells and Specimen Adequacy
Atypical Epithelial Cells and Specimen Adequacy Current Laboratory Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology Diane
More informationUtility of Pap Smear in Cervical Screening in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 1 (2017) pp. 319-323 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2017.601.039
More informationPage # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases:
Endometrium Pathology of the Endometrium Thomas C. Wright Columbia University, New York, NY Most common diseases: Abnormal uterine bleeding Inflammatory conditions Benign neoplasms Endometrial cancer Anatomical
More informationAtypical Hyperplasia/EIN
EIN Atypical Hyperplasia/EIN Based on scientific and diagnostic advances, in 2014 the WHO moved that the precursor lesion for endometrioid carcinoma be atypical hyperplasia/ein, rather than what was previously
More informationAssessment of Transvaginal Sonography Combined with Endometrial Cytology as a Mass Screening Method for Endometrial Cancer in Beijing
The Journal of International Medical Research 2010; 38: 803 809 [first published online as 38(3) 1] Assessment of Transvaginal Sonography Combined with Endometrial Cytology as a Mass Screening Method for
More informationEndometrial Hyperplasia: A Clinicopathological Study in a Tertiary Care Hospital
DOI 10.1007/s13224-013-0414-2 ORIGINAL ARTICLE Endometrial Hyperplasia: A Clinicopathological Study in a Tertiary Care Hospital Raychaudhuri Gargi Bandyopadhyay Anjali Sarkar Dipnarayan Mandal Sarbeswar
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationHysterectomy : A Clinicopathologic Correlation
Bahrain Medical Bulletin, Vol. 28, No.2, June 2006 Hysterectomy : A Clinicopathologic Correlation Layla S Abdullah, FRCPC* Objective : To study the most common pathologies identified in hysterectomy specimens
More informationNegative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
Anatomic Pathology / FALSE-NEGATIVE HISTOLOGIC FINDINGS Negative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationSydney Gynaecology Oncology Group, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
bs_bs_banner doi:10.1111/jog.12545 J. Obstet. Gynaecol. Res. Vol. 41, No. 3: 440 444, March 2015 Abnormal cervicovaginal cytology, unsatisfactory colposcopy and the use of vaginal estrogen cream: An observational
More informationCervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens
Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens 3 Christine Bergeron, MD, PhD Introduction Carcinoma of the cervix is a slow growing cancer, which is preceded by precancerous
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006 Galen M. Eversole, MD; Ann T. Moriarty,
More informationPAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals
PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals Historical Named after George Papanicolaou, a Greek American Studied cervical epithelium in menstrual cycle of guinea
More informationPap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???
Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed??? Arlene Evans-DeBeverly, PA-C Copyright 2012 There are always ongoing changes in gynecology, including the
More informationResearch. Breast cancer represents a major
Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationClinical Utility of Adjunctive High-Risk Human Papillomavirus DNA Testing in Women With Papanicolaou Test Findings of Atypical Glandular Cells
Clinical Utility of Adjunctive High-Risk Human Papillomavirus DNA Testing in Women With Papanicolaou Test Findings of Atypical Glandular Cells Chengquan Zhao, MD; Anca Florea, MD; R. Marshall Austin, MD,
More informationIn 1988, the National Cancer Institute developed the Bethesda System. Atypical Squamous Cells of Undetermined Significance on Cervical Smears CANCER
74 CANCER CYTOPATHOLOGY Atypical Squamous Cells of Undetermined Significance on Cervical Smears Follow-Up Study of an Asian Screening Population Annie N. Y. Cheung, M.D. Elaine F. Szeto, B.Sc. Kin-Man
More informationA clinical review of borderline glandular cells reported on liquid-based cervical cytology
DOI: 10.1111/j.1471-0528.2009.02477.x www.bjog.org Gynaecological oncology A clinical review of borderline glandular cells reported on liquid-based cervical cytology A Patel, a N Thampy, b D Hemming, b
More informationMaterials and Methods
Accuracy of Diagnosis of Atypical Glandular Cells Conventional and ThinPrep Reena Ramsaroop, M.B., Ch.B., F.F.Path., Ph.D.* and Ien Chu, N.Z.I.M.L.T., Q.T.A., Q.T.O. The incidence of glandular cervical
More informationINTRODUCTION HSIL AND CERVICAL CARCINOMA IN ASCUS CERVICAL CYTOLOGY
HSIL AND CERVICAL CARCINOMA IN ASCUS CERVICAL CYTOLOGY PREVALENCE OF HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) AND INVASIVE CERVICAL CANCER IN PATIENTS WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED
More informationCytology Update M Laing QEUH
Cytology Update M Laing QEUH Age change to 25 to 65 Age 25 to 50 Three yearly smear invitation Age 50 to 65 Five yearly smear invitation Women on non routine screening will be invited up to age 70 OUTCOME
More informationCytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium
Jpn J Clin Oncol 2003;33(12)636 641 Cytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium Yukiharu Todo, Shinichirou Minobe, Kazuhira Okamoto, Mahito Takeda, Yasuhiko Ebina,
More informationFemale Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan
Female Genital Tract Lab Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan Ovarian Pathology A 20-year-old female presented with vague left pelvic pain. Pelvic exam revealed
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationCorrelation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding
DOI 10.1007/s13224-014-0627-z ORIGINAL ARTICLE Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding Singh Pushpa Dwivedi Pooja Mendiratta Shweta
More informationEndometrial line thickness in different conditions.
Endometrial line thickness in different conditions 1 Endometrial thickens in response to Rising estrogen levels during the menstrual cycle and then shedding endometrial at the times of menses 2 The thickens
More informationDeclining endocervical rates: does it matter? Dorota Gertig Medical Director, VCCR
Declining endocervical rates: does it matter? Dorota Gertig Medical Director, VCCR Background Outline Current recommendations Australian and international Review key studies Data from AIHW and VCCR Analysis
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationRepeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results
Anatomic Pathology / REPEAT THYROID FINE-NEEDLE ASPIRATION Repeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results Melina B. Flanagan, MD, MSPH, 1 N. Paul Ohori,
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationCase 3 - GYN. History: 66 year old, routine Pap test. Dr. Stelow
Case 3 - GYN History: 66 year old, routine Pap test Dr. Stelow Case 3 66 year year old woman Routine Pap Test Cytologic Features 3 dimensional clusters of cells with small to moderate amount of
More informationSuspicious Cytologic Diagnostic Category in Endoscopic Ultrasound-Guided FNA of the Pancreas: Follow-Up and Outcomes
Suspicious Cytologic Diagnostic Category in Endoscopic Ultrasound-Guided FNA of the Pancreas: Follow-Up and Outcomes Evan A. Alston, MD 1 ; Sejong Bae, PhD 2 ; and Isam A. Eltoum, MD, MBA 1 BACKGROUND:
More informationPerimenopausal Age Group (45-55yrs): For Early Detection And Treatment.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 9 Ver. 4 (September. 2018), PP 73-77 www.iosrjournals.org Perimenopausal Age Group (45-55yrs):
More informationClinical Outcome for Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations Should Repeated FNA Be the Preferred Initial Approach?
Anatomic Pathology / Clinical Outcome for AUS Thyroid FNA Clinical Outcome for Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations Should Repeated FNA Be the Preferred Initial Approach?
More informationBOSNIAN-TURKISH CYTOPATHOLOGY SCHOOL June 18-19, 2016 Sarajevo. Case Discussions. 60 year old woman Routine gynecologic control LBC
BOSNIAN-TURKISH CYTOPATHOLOGY SCHOOL June 18-19, 2016 Sarajevo Case Discussions Prof Dr Sıtkı Tuzlalı Tuzlalı Pathology Laboratory 60 year old woman Routine gynecologic control LBC 1 2 Endometrial thickening
More informationDETECTING CELLS USING IMAGE SEGMENTATION OF THE CERVICAL CANCER IMAGES TAKEN FROM SCANNING ELECTRON MICROSCOPE
DETECTING CELLS USING IMAGE SEGMENTATION OF THE CERVICAL CANCER IMAGES TAKEN FROM SCANNING ELECTRON MICROSCOPE Sevcan AYTAÇ KORKMAZ Fırat University, Department of Electronic Technology, Elazığ- TURKEY
More informationHyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000
Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000 Thomas A. Bonfiglio, M.D. Professor Emeritus, Pathology and Laboratory Medicine University of Rochester Disclosures In the past 12 months,
More informationMehmet Coskun Salman 1, Alp Usubutun 2, Kubra Boynukalin 1, Kunter Yuce 1 INTRODUCTION
J Gynecol Oncol Vol. 21, No. 2:97-101, June 2010 DOI:10.3802/jgo.2010.21.2.97 Original Article Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of
More informationCan LBC Completely Replace Conventional Pap Smear in Developing Countries
The Journal of Obstetrics and Gynecology of India (January February 2019) 69(1):69 76 https://doi.org/10.1007/s13224-018-1-7 ORIGINAL ARTICLE Can LBC Completely Replace Conventional Pap Smear in Developing
More informationName of Policy: Speculoscopy
Name of Policy: Speculoscopy Policy #: 095 Latest Review Date: September 2011 Category: Medicine/OB Gyn Policy Grade: C Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationAbnormal Uterine Bleeding. Richard Dover Specialist gynaecologist
Abnormal Uterine Bleeding Richard Dover Specialist gynaecologist A pragmatic guide. Wide topic range What s not coming up Precocious puberty Menorrhagia well maybe just a little Topics Adolescents IMB
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationCytology and Surgical Pathology of Gynecologic Neoplasms
Cytology and Surgical Pathology of Gynecologic Neoplasms Current Clinical Pathology ANTONIO GIORDANO, MD, PHD SERIES EDITOR For further titles published in this series, go to http://www.springer.com/springer/series/7632
More informationLET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy
THERAPUTIC AGENTS: ARE THEY SAFE? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University School of Medicine Director of Gynecologic Ultrasound Co-Director of Bone Densitometry
More informationdifficult and may not be practical. Nevertheless, the performance characteristics of rapid screening have not been completely characterized.
Anatomic Pathology / PERFORMANCE CHARACTERISTICS OF RAPID PRESCREENING Performance Characteristics of Rapid (0-Second) Prescreening Implications for Calculating the False-Negative Rate and Comparison With
More informationThe AutoPap Primary Screening System (APSS; Tripath Imaging,
CANCER CYTOPATHOLOGY 129 A Feasibility Study of the Use of the AutoPap Screening System as a Primary Screening and Location-Guided Rescreening Device Massimo Confortini, M.D. 1 Lucia Bonardi, M.D. 1 Paolo
More informationCamelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program
Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program A B C D USPSTF recommends the service. There is high certainty that Offer or provide
More informationUterine Morcellation: Teasing Out the Issues
Uterine Morcellation: Teasing Out the Issues Stacey A. Scheib, MD, FACOG Director, Minimally Invasive Gynecology Director, Hopkins Multidisciplinary Fibroid Center Johns Hopkins Hospital Disclosures I
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Comparison of Performance of Conventional and ThinPrep Gynecologic Preparations in the College of American Pathologists Gynecologic Cytology Program Andrew A. Renshaw,
More informationAssociate Professor of Gyn. & Obs., Department of Gynecology and Obstetrics, Tehran University of Medical Sciences, Iran.
Assessment of Visual Inspection with Acetic Acid (VIA) as a Screening Test for Cervical Neoplasia in Comparison with Cytologic Screening in Imam Khomeini Hospital F. Ghaemmaghami, MD Associate Professor
More informationObjectives. Atypical Glandular Cells. Atypical Endocervical Cells. Reactive Endocervical Cells
2013 California Society of Pathologists 66 th Annual Meeting San Francisco, CA Atypical Glandular Cells to Early Invasive Adenocarcinoma: Cervical Cytology and Histology Christina S. Kong, MD Associate
More informationComparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination
ORIGINAL ARTICLE Comparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination Numi Anjum 1, B Sindhoora 2 1. Tutor, Department of Obstetrics and Gynecology
More information